Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 18/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 14/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648960 | 0.89 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL5645071 | 0.85 | PTGS2 (0.46) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5645353 | 0.85 | PTGS2 (0.41) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5642966 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5645829 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL6092049 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5643925 | 0.82 | PTGS2 (0.46) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5646666 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5645779 | 0.80 | PTGS2 (0.45) | PTGS2PTGS1NFKB1NFKB2RELA | |
| SCHEMBL5645157 | 0.79 | PTGS2 (0.51) | PTGS2PTGS1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | ADRA2A 428/4885DRD5 2695/4885DRD3 1390/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | ADRA2A 618/4885DRD5 3056/4885DRD3 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.